OM1, a Boston, MA-based real-world outcomes and technology company, closed a $50m Series C financing round.

The round was led by Scale Venture Partners, with participation from existing investors General Catalyst (GC), Polaris Partners, and 7wire Ventures.

In conjunction with the funding, Rory O’Driscoll, Partner at Scale Venture Partner, has joined OM1’s Board of Directors.

The company intends to use the funds to expand its real-world data cloud and clinical registries for real-world evidence and personalized medicine.

The company focuses on specific therapeutic areas, including chronic conditions like immunology, rheumatology, cardiometabolic disorders, musculoskeletal conditions and central nervous system (CNS)/behavioral health. | To read full story, visit https://startuparound.com/read/1576706411.2429247/OM1-Closes-$50M-Series-C-Financing?ref=audio_experience